Designing Antibody-Based Degraders to Overcome ADC Limitations & Unlock New Therapeutic Opportunities for TPD
As antibody-derived degraders emerge as a powerful alternative to small molecules, this workshop will teach you how to engineer and optimise these biologics to unlock new extracellular degradation strategies.
We will cover:
- Comparing antibody-based degraders with PROTACs and molecular glues to highlight expanded E3 ligase use and tissue-specific targeting enabled by Laigo’s platform
- Leveraging NANOBODY® VHH and antibody engineering to enable precise target engagement and novel extracellular degradation strategies
- Elucidating biodistribution and internalisation pathways to ensure targeted delivery of DACs and minimise off-target effects across tissues and cell types
This workshop is ideal for scientists exploring how antibody-derived scaffolds can extend targeted protein degradation beyond intracellular targets.